Overview

Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Status:
Recruiting

Trial end date:
2022-02-28

Target enrollment:

Participant gender:

Summary

This multicenter, randomized, double-blind study will evaluate the efficacy and safety of Toripalimab (JS001) combined with nab-paclitaxel compared with placebo combined with nab-paclitaxel for first/second line treatment of metastatic or recurrent triple-negative breast cancer (TNBC).

Phase:

Phase 3

Details

Lead Sponsor:

Shanghai Junshi Bioscience Co., Ltd.

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel